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Japanese encephalitis (JE) occurs in rural settings in southern and eastern Asia, where diagnostic facilities
are limited. For the diagnosis of JE virus (JEV) infection, we developed a nitrocellulose membrane-based
immunoglobulin M (IgM) capture dot enzyme immunoassay (MAC DOT) that is rapid, simple to use, requires
no specialized equipment, and can distinguish JEV from dengue infection. In a prospective field study in
southern Vietnam, 155 cerebrospinal fluid (CSF) and 341 serum samples were collected from 111 children and
83 adults with suspected encephalitis. The JEV MAC DOT, performed on site, was scored visually from
negative to strongly positive by two observers, and the results were compared subsequently with those of the
standard IgM capture enzyme-linked immunosorbent assay. For the 179 patients with adequate specimens, the
MAC DOT correctly identified 59 of 60 JEV-positive patients and 118 of 119 JEV-negative patients (sensitivity
[95% confidence intervals], 98.3% [92.1 to 99.9%]; specificity, 99.2% [95.9 to 100.0%]; positive predictive value,
0.98; negative predictive value, 0.99). The MAC DOT also correctly identified three patients with dengue
encephalopathy. Admission specimens were positive for 73% of JE patients. Interobserver agreement for MAC
DOT diagnosis was excellent (kappa 5 0.94). The JEV MAC DOT is a simple and reliable rapid diagnostic test
for JE in rural hospitals.
Japanese encephalitis virus (JEV) is the most common cause
of viral encephalitis in the world, causing an estimated 45,000
cases and 10,000 deaths annually (24). Up to 50% of survivors
are left with severe neurological sequelae. Most cases occur in
southern and eastern Asia. JEV is a member of the genus
Flavivirus (family Flaviviridae) that is transmitted between
birds, pigs, and some other domestic animals by Culex mosqui-
tos (16, 22). Humans are an incidental host, infected when
living or passing in close proximity to this enzootic cycle.
Hence, most infections of humans occur in rural tropical areas,
where facilities for diagnosis are limited.
Even with the best laboratory facilities, JEV cannot usually
be isolated from clinical specimens, probably because of low
circulating viral numbers and the rapid development of neu-
tralizing antibodies (2). The diagnosis is therefore usually
made serologically (16). For many years, the hemagglutination
inhibition test has been employed, but this has various practical
limitations. Most importantly, it requires paired serum samples
and cannot therefore give an early diagnosis (12). In the 1980s,
an antibody capture radioimmunoassay was developed (6); this
was soon replaced by simpler enzyme-linked immunosorbent
assays (ELISAs) (3, 17). The immunoglobulin M (IgM) anti-
body capture ELISA (MAC ELISA) for serum and cerebro-
spinal fluid (CSF) has become the accepted standard for diag-
nosis of Japanese encephalitis (JE) (16). This assay is sensitive
and specific; it is often positive for specimens collected on
admission and distinguishes between JEV and the related den-
gue flaviviruses, which are serologically cross-reactive. How-
ever, because these ELISAs require sophisticated equipment,
their use has been confined largely to a few academic or re-
ferral centers. Since most patients with JE are seen in rural
hospitals with limited facilities, there is a need for a simple and
reliable diagnostic test which is appropriate for such settings.
Recently, the diagnosis of dengue virus infection has been
simplified with a modification of the dengue virus MAC
ELISA: IgM capture antibody is dotted onto a nitrocellulose
membrane, and the result of the assay is a color change visible
to the naked eye (8). This dengue virus IgM dot enzyme im-
munoassay (MAC DOT) requires no specialized skills or
equipment and has been validated both in the laboratory (8)
and in multicenter field studies (19). It is becoming an ac-
cepted means of diagnosing dengue virus infections. We report
here the development and field trial of a similar IgM dot
enzyme immunoassay for JEV, which is able to distinguish
between infection by dengue viruses and that by JEV.
MATERIALS AND METHODS
Virus antigen preparation. Viral antigens were prepared by growing JEV
(Nakayama strain) and dengue viruses (DEN 1 Hawaii, DEN 2 New Guinea C,
DEN 3 H-87, and DEN 4 H-241) in C6/36 Aedes albopictus as described previ-
ously (8). Control antigens were prepared similarly from cell culture superna-
tants of mock-infected C6/36 cells. The antigen titer of each harvest was tested
by dot enzyme immunoassay using pooled convalescent-phase patient serum as
described previously (11). Supernatants giving a clear positive reaction at a
dilution of 1:10,000 were pooled. For dengue virus antigens, a cocktail of equal
volumes of all four serotypes was prepared.
Membrane preparation. Rabbit anti-human IgM m chain (A425; Dakopatts,
Copenhagen, Denmark) was spotted onto nitrocellulose membranes (MFS,
Pleasanton, Calif.; pore size, 0.45 mm) in 5-ml drops at a 1:250 dilution, and the
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membranes were allowed to dry in air. Unbound sites were then blocked with
phosphate-buffered saline containing 5% nonfat skim milk (PBS-SM), and the
membranes were washed in distilled water and air dried before storage at 4°C.
Clinical evaluation. This study was conducted at the Centre for Tropical
Diseases, Ho Chi Minh City, Vietnam, an infectious disease referral hospital for
southern Vietnam. In this area, both JEV and dengue virus infections are
endemic. The study protocol was approved by the hospital’s scientific and ethical
committee, and consent for entry was obtained from the patients’ relatives.
Between March 1996 and August 1997, children and adults with suspected
encephalitis were investigated as part of a prospective clinicopathological study
of central nervous system infections. Encephalitis was suspected in patients with
a fever and clouding of consciousness (Glasgow coma scale of #14 [23]), con-
vulsions, or focal neurological signs with no other obvious cause. CSF was
collected on admission, and, where possible, 7 days later. Serum was collected on
admission, at 7 days, and at discharge. Samples were divided into two aliquots
and stored at 270°C before assay.
MAC DOT. Anti-JEV and anti-dengue virus IgM antibodies were assessed in
CSF and sera by using an approach similar to that of the dengue virus MAC
DOT test (Venture Technologies, Sarawak, Malaysia) described previously (9)
but with samples assessed for JEV and dengue virus antibodies in parallel. MAC
DOT membranes were incubated for 2 h at ambient room temperature (25 to
30°C) with serum (diluted 1:100 in PBS-SM) or CSF (diluted 1:5). Following this,
JEV or dengue virus antigen was added for overnight incubation at 4°C. The
membranes were then incubated with monoclonal antibodies reactive to JEV
(MV12/1/C2-2) or dengue (MF4/5/A5/C3-3/D4) for 1 h at room temperature,
followed by rabbit anti-mouse immunoglobulin conjugated with horseradish per-
oxidase (Dakopatts) at a dilution of 1:1,000 for 1 h at room temperature. Be-
tween each step, the membranes were washed three times in phosphate-buffered
saline for 5 min. Bound antibody was visualized by using a chromogenic substrate
of 4-chloro-1-naphthol and hydrogen peroxide. The reaction was stopped after
30 min by washing with distilled water, and the membranes were air dried. All
samples producing a blue circle were considered to contain detectable levels of
JEV or dengue virus IgM. Color intensities were classified as described below.
Negative and positive controls for JEV and dengue virus were included in each
run. Depending on the number of samples to be tested, up to 20 samples could
be studied simultaneously. This test was developed by one of us (M.J.C.) in a
form that is now available commercially (Venture Technologies).
MAC ELISA. Anti-JEV and anti-dengue virus IgM antibodies were measured
in CSF and sera by using a double sandwich capture ELISA, as described
previously (17). For single serum and CSF specimens, 40 U of anti-JEV IgM
(with anti-JEV IgM greater than anti-dengue virus IgM), or for paired samples
an increase from less than 15 U to 30 U or more, was considered evidence of JEV
infection (17). Dengue virus infection was diagnosed if the dengue virus IgM titer
was greater than the JEV IgM titer (21). Elevated CSF IgM was considered
diagnostic of central nervous system infection (6, 7). Patients with negative
paired serum samples or a single negative convalescent-phase sample were con-
sidered to be not infected with a flavivirus. Patients who had only an acute-phase
sample that was negative were classed as having no serological diagnosis.
In an open pilot study using samples from 20 patients with suspected enceph-
alitis (data not shown), the MAC DOT and MAC ELISA results were compared
to allow MAC DOT color intensities to be scored as follows: negative, no color
change; very weakly positive, barely visible blue circle; weakly positive, circle
visible but fainter than that of the positive control; positive, circle visible to a
degree approximately equal to that of the positive control; strongly positive,
stronger color than that of positive control. Only reactions greater than or equal
to that of the positive control (i.e., scored positive or strongly positive) were
considered diagnostic of infection. Where there was a reaction in both the JEV
and dengue virus wells, the stronger reaction was considered diagnostic. After
the pilot study, samples were tested independently in two centers (by the MAC
DOT in Vietnam and the MAC ELISA in Thailand), blinded to the patient
details and with no discussion of results until the study was completed. The MAC
DOT result was scored independently by two observers, and if the observers
disagreed, a third deciding opinion was sought. For comparisons with the MAC
ELISA, only the final agreed MAC DOT result was used.
Statistical analysis. Interobserver agreement for the MAC DOT results was
assessed by using the kappa statistic as a measure of agreement. Values of kappa
ranging from 0 (no agreement) to 1.00 (perfect agreement) were interpreted as
follows: 0.0 to 0.2, poor; 0.21 to 0.40, fair; 0.41 to 0.60, moderate; 0.61 to 0.80,
good; 0.81 to 1.00, very good (1).
RESULTS
In total, 496 samples (155 CSF and 341 serum samples) from
194 patients (111 children and 83 adults) with suspected en-
cephalitis were assessed. The serological diagnoses given by
the MAC ELISA were JEV infection (60 patients), dengue
virus infection (3 patients), and no flavivirus infection (116
patients). No serological diagnosis could be made for the 15
patients from whom only an acute-phase sample was available,
either because they died (n 5 3) or because they left hospital
soon after admission (e.g., children with febrile convulsions).
Serology. The MAC DOT correctly identified 43 of 52 pos-
itive CSF samples (sensitivity [95% confidence intervals], 83%
[71 to 91%]; specificity, 99% [95 to 100%]; positive predictive
value [PPV], 0.98; negative predictive value [NPV], 0.92) and
121 of 133 positive serum samples (sensitivity, 91% [85 to
95%]; specificity, 95% [92 to 98%]; PPV, 0.92; NPV, 0.94)
(Table 1). The nine positive CSF samples misclassified by the
MAC DOT consisted of seven scored as weakly positive and
two scored as negative. The 12 positive serum samples misclas-
sified (i.e., the false negatives) consisted of 8 scored as weakly
positive and 4 scored as very weakly positive (Fig. 1). In most
cases where the CSF and serum samples were falsely negative,
the samples were collected early in the course of the disease
and subsequent samples were positive. Combining the CSF
TABLE 1. Comparison of JEV results by MAC DOT and MAC
ELISA for 496 samples
Sample type and MAC
DOT results
MAC ELISA results (no. of samples)
JEV positive JEV negative Total no.of samples
CSF
JEV positive 43 1 44
JEV negative 9 102 111
Total 52 103 155
Serum
JEV positive 121 10 131
JEV negative 12 198 210
Total 133 208 341
FIG. 1. Comparison of JEV MAC DOT test score and JEV IgM measured
by MAC ELISA. The broken line is the cutoff for a positive MAC ELISA (40 U).
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and serum results, the MAC DOT correctly identified 59 of 60
JEV-positive patients and 118 of 119 JEV-negative patients
(sensitivity [95% confidence intervals], 98.3% [92.1 to 99.9%];
specificity, 99.2% [95.9 to 100%]; PPV, 0.98; NPV, 0.99). The
MAC DOT also identified three dengue virus-positive patients
correctly (two with elevated IgM in serum only, the third with
elevated IgM in serum and CSF). The MAC DOT misdiag-
nosed three (1.5%) patients, one false negative for JEV infec-
tion, one false positive for JEV infection, and one false positive
for dengue virus infection. The patient with false-negative re-
sults was scored by MAC DOT as weakly positive for JEV in
both CSF and serum samples, but the MAC ELISA results
were positive (86 U of IgM in CSF and 129 U of IgM in
serum). One patient with a measurement of 34 U of anti-JEV
IgM in serum by the MAC ELISA was scored as positive for
JEV infection by the MAC DOT. The patient with a false-
positive dengue virus infection diagnosis had 25 U of anti-
dengue virus IgM in serum but was scored as dengue virus
positive by the MAC DOT. Of the JEV-positive patients, 45
(75%) were diagnosed by the MAC DOT with their first serum
sample, and 29 (63%) of 46 CSF samples collected at admis-
sion were positive. Equivalent figures for the MAC ELISA
were 45 (75%) for serum samples and 37 (80%) for CSF
samples. The relationship between duration of disease and test
positivity is shown in Fig. 2. By day 4, 57% of CSF samples and
60% of serum samples were positive by the MAC DOT.
Interobserver agreement. The MAC DOT results scored by
the two observers are compared in Table 2. Interobserver
agreement for all samples was very good, with a kappa value of
0.83; it was slightly better for CSF samples (kappa 5 0.89) than
for serum samples (kappa 5 0.80). When the MAC DOT
scores were considered with regard to diagnosis of JEV infec-
tion (scores of negative, very weakly positive, and weakly pos-
itive 5 negative for infection; scores of positive and strongly
positive 5 positive for infection), the interobserver agreement
was even better, with a kappa value of 0.94.
DISCUSSION
In the last 50 years, the epidemiology of JEV has changed.
While mass vaccination campaigns have been associated with a
decrease in the number of encephalitis cases in Japan, Taiwan,
and South Korea, the geographic area affected by the virus has
expanded to include the Indian subcontinent, China, Southeast
Asia, and the Western Pacific region (22). The reasons for this
expansion are incompletely understood, but increasing irriga-
tion and animal husbandry favoring breeding of the Culex
mosquito vector are thought to be important. Approximately
2.8 billion people live in this vast geographical area, and JE is
likely to remain an important public health problem into the
21st century. Two epidemiological patterns are recognized: in
temperate climates, JE occurs in epidemics, while in tropical
climates, the disease is endemic with sporadic cases throughout
the year. Estimates of the annual incidence of JE range from
35,000 to 50,000 (13, 15), but the true number is unknown,
because most areas where JEV occurs lack diagnostic facilities.
Although there is currently no effective antiviral treatment, the
importance of diagnosing Japanese encephalitis extends be-
yond epidemiological interest. A correct diagnosis focuses the
physician’s attention on the specific complications of JE such
as hyponatremia, convulsions, and raised intracranial pressure
(14, 16, 18) and avoids continued investigation and possibly
inappropriate treatment of other central nervous system infec-
tions. In some countries, vaccination campaigns can be mobi-
lized and targeted towards areas where patients with JE orig-
inate; in others, vaccination will not be introduced without
good epidemiological support.
The diagnosis of JE has advanced considerably in the last 20
years. The MAC ELISA overcame many of the problems as-
sociated with hemagglutination inhibition tests, namely, the
need for paired serum samples, acetone extraction of serum,
serial dilutions, and the lack of specificity among secondary
flaviviruses infections. The MAC ELISA, scored by visual ex-
amination, has been assessed in the field and has performed
well (5). However, since it uses 96-well plates, the MAC
ELISA is more appropriate for investigating large numbers of
samples in diagnostic centers rather than individual patients in
small rural hospitals. Field diagnosis of flavivirus infections
advanced in the 1990s with the development of nitrocellulose
membrane-based enzyme immunoassays. In the first dot en-
zyme immunoassays, viral antigen from JEV, dengue virus, or
other viruses was dotted onto a nitrocellulose membrane (9,
10, 11). Since these were not antibody isotype specific, they
were appropriate for serological surveys rather than for diag-
nosis of acute infection. With modification to an IgM isotype
capture form, clinical diagnosis became possible. The dengue
FIG. 2. MAC ELISA units (A) and proportion (percentage) of CSF (B) and
serum (C) samples positive by MAC DOT and MAC ELISA, by day of illness in
patients with JE.
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virus MAC DOT has proved reliable in diverse field settings in
Southeast Asia, the South Pacific, and South America (8, 19),
with sensitivity and specificity around 90%. It has recently been
modified to a more rapid colloidal gold-based immunochro-
matographic format (25). In the present study, we have shown
the JEV MAC DOT to be equally reliable. Combining the
serum and CSF test results, the MAC DOT correctly identified
59 of 60 patients infected with JEV, as detected by the MAC
ELISA, with sensitivity and specificity over 98% and excellent
interobserver agreement. Overall, 75% of infected patients
were identified by the admission specimen results and the
sensitivity and specificity of the test for individual serum sam-
ples were greater than 90%. For CSF samples, the sensitivity
was lower (83%), but our initial cutoff may have been too high.
When a diagnosis of infection was based on an anti-JEV reac-
tion score of weakly positive, positive, or strongly positive, 50
of 52 JEV-positive CSF samples and 100 of 103 JEV-negative
CSF samples (sensitivity [95% confidence intervals], 96% [88
to 99%]; specificity, 97% [92 to 99%]; PPV, 0.94; NPV, 0.98)
were correctly identified. A priori this seems a reasonable
approach, since any IgM antibody in the CSF is likely to be
diagnostic (7).
The majority of infections with JEV do not lead to enceph-
alitis. Estimates of the ratio of apparent to inapparent infec-
tions range from 1:25 to 1:300 (22). Asymptomatic infections
are associated with elevated IgM in the serum only. The pres-
ence of IgM in the CSF indicates active antibody production by
the central nervous system in response to JEV infection (7).
Sensitivity and specificity are both greater than 95% after the
seventh day after admission (16). Samples taken earlier may be
negative, and hence it is recommended that serum and CSF
antibodies be measured upon admission and on day 7 (16).
Most patients infected with JEV will be identified by MAC
DOT and MAC ELISA; however, a subgroup of patients die
soon after hospital admission, before producing an antibody
response (4). This may have been the case for three patients in
this study who died without a serological diagnosis. Virus iso-
lation may be positive for these patients, especially from post-
mortem brain tissue (20), but unfortunately such tissue was not
available.
Many of the areas which are endemic for JEV are also
endemic for dengue viruses. In the past, all encephalopathic
patients with antibody reactive to JEV were assumed to have
JE, but neurological manifestations of dengue virus infections
are gaining increasing recognition (21, 22). In this study, the
MAC DOT and the MAC ELISA identified three patients with
higher antibody levels to dengue viruses than to JEV, including
one with antibody in the CSF. Only by measuring antibody
levels to JEV and to dengue virus in parallel can the two be
distinguished. Further use of the JEV MAC DOT may help,
not only in the identification of patients with JE but also in the
identification of patients with neurological manifestations of
dengue virus infection.
In summary, the JEV MAC DOT is a rapid and reliable
diagnostic test for JE. The only electrical equipment it requires
is a refrigerator. Its simplicity and long storage life (12 months
at 4°C) make it appropriate for use in rural hospitals. Since it
is now commercially produced, it should become widely avail-
able and make a useful contribution to the diagnosis, manage-
ment, and epidemiology of Japanese encephalitis.
ACKNOWLEDGMENTS
We are grateful to the Director and staff of the Centre for Tropical
Diseases, in particular the doctors and nurses of the adult and pediatric
intensive care units; Pham Thi Diep, Pham Thi Doan, Nguyen Thu
Quyen, and Panor Srisongkram for laboratory support; Delia Bethell,
Nicholas Day, Deborah House, Christopher Parry, and John Wain for
helpful discussions; and Tio Phaik Hooi for preparing reagents. MAC
DOT reagents were provided by Venture Technologies, UNIMAS
Research Park, Universiti Malaysia Sarawak, Sarawak, Malaysia.
This work was funded by The Wellcome Trust of Great Britain.
REFERENCES
1. Altman, D. G. 1993. Practical statistics for medical research. TJ Press (Pad-
stow) Ltd., Padstow, Cornwall, United Kingdom.
2. Buescher, E. L., and W. F. Scherer. 1959. Immunological studies of Japanese
encephalitis virus in man. I. Antibody responses following overt infection of
man. J. Immunol. 83:582–593.
3. Bundo, K., and A. Igarashi. 1985. Antibody-capture ELISA for detection of
immunoglobulin M antibodies in sera from Japanese encephalitis and den-
gue hemorrhagic fever patients. J. Virol. Methods 11:15–22.
4. Burke, D. S., W. Lorsumrudee, C. J. Leake, C. H. Hoke, A. Nisalak, and T.
Laorakpongse. 1985. Fatal outcome in Japanese encephalitis. Am. J. Trop.
Med. Hyg. 34:1203–1209.
5. Burke, D. S., A. Nisalak, and C. H. Hoke. 1986. Field trial of a Japanese
encephalitis diagnostic kit. J. Med. Virol. 18:41–49.
6. Burke, D. S., A. Nisalak, and M. A. Ussery. 1982. Antibody capture immu-
noassay detection of Japanese encephalitis virus immunoglobulin M and G
antibodies in cerebrospinal fluid. J. Clin. Microbiol. 16:1034–1042.
7. Burke, D. S., A. Nisalak, M. A. Ussery, T. Laorakpongse, and S. Chanta-
vibul. 1985. Kinetics of IgM and IgG responses to Japanese encephalitis virus
in human serum and cerebro-spinal fluid. J. Infect. Dis. 151:1093–1099.
8. Cardosa, M. J., F. Baharudin, S. Hamid, T. P. Hooi, and S. Nimmannitya.
1995. A nitrocellulose membrane based IgM capture enzyme immunoassay
for etiologic diagnosis of dengue virus infections. Clin. Diagn. Virol. 3:343–
350.
9. Cardosa, M. J., F.-L. Hah, B.-H. Choo, and S. Padmanathan. 1993. Screen-
ing of pig sera for antibodies to Japanese encephalitis virus using a dot
enzyme immunoassay and IgM capture ELISA: comparison with the haem-
agglutination inhibition and plaque reduction neutralization tests. Southeast
Asian J. Trop. Med. Public Health 24:472–6.
10. Cardosa, M. J., H. S. Tan, Z. Ismail, and P. H. Tio. 1991. Use of a dot
enzyme immunoassay for determination of antibodies to a multianalyte pan-
el: applications for rapid screening of population for antibody profiles. Trop.
Biomed. 8:151–156.
11. Cardosa, M. J., and P. H. Tio. 1991. Dot enzyme immunoassay: an alterna-
tive diagnostic aid for dengue fever and dengue hemorrhagic fever. Bull.
W. H. O. 69:741–745.
12. Clark, C. H., and J. Casals. 1958. Techniques for hemagglutination inhibi-
TABLE 2. Interobserver agreement of MAC DOT results for 496 samples
Observer 1 results
Observer 2 results (no. of samples)
Total no.





Negative 198 15 3 0 0 216
Very weakly positive 12 37 6 0 0 55
Weakly positive 3 2 32 7 0 44
Positive 0 1 6 88 5 100
Strongly positive 0 0 0 1 80 81
Total 213 55 47 96 85 496
VOL. 36, 1998 IgM DOT IMMUNOASSAY FOR JAPANESE ENCEPHALITIS 2033












tion with arthropod viruses. Am. J. Trop. Med. Hyg. 7:561–573.
13. Hennessy, S., L. Zhengle, T. F. Tsai, B. L. Strom, W. Chao-Min, L. Hui-Lian,
W. Tai-Xiang, Y. Hong-Ji, L. Qi-Mau, N. Karabatsos, W. B. Bilker, and S. B.
Halstead. 1996. Effectiveness of live-attenuated Japanese encephalitis vac-
cine (SA14-14-2): a case control study. Lancet 347:1583–1586.
14. Hoke, C. H., D. W. Vaughn, A. Nisalak, P. Intralawan, S. Poolsuppasit, V.
Jongsawas, U. Titsyakorn, and R. T. Johnson. 1992. Effect of high dose
dexamethasone on the outcome of acute encephalitis due to Japanese en-
cephalitis virus. J. Infect. Dis. 165:631–637.
15. Igarashi, A. 1992. Epidemiology and control of Japanese encephalitis. World
Health Stat. Q. 45:299–305.
16. Innis, B. L. 1995. Japanese encephalitis, p. 147–174. In J. S. Porterfield (ed.),
Exotic viral infections. Chapman & Hall, London, United Kingdom.
17. Innis, B. L., A. Nisalak, S. Nimmannitya, S. Kusalerdchariya, V. Chongs-
wasdi, S. Suntayakorn, P. Puttisri, and C. H. Hoke. 1989. An enzyme-linked
immunosorbent assay to characterize dengue infections where dengue and
Japanese encephalitis co-circulate. Am. J. Trop. Med. Hyg. 40:418–427.
18. Kumar, R., A. Mathur, A. Kumar, S. Sharma, S. Chakraborty, and U. C.
Chaturvedi. 1990. Clinical features and prognostic indicators of Japanese
encephalitis in children in Lucknow (India). Indian J. Med. Res. 91:321–327.
19. Lam, S. K., M. Y. Fong, E. Chungue, S. Doraisingham, A. Igarashi, M. A.
Khin, Z. T. Kyaw, A. Nisalak, C. Roche, D. W. Vaughn, and V. Vordnam.
1996. Multicentre evaluation of dengue IgM dot enzyme immunoassay. Clin.
Diagn. Virol. 7:93–98.
20. Leake, C. J., D. S. Burke, A. Nisalak, and C. H. Hoke. 1986. Isolation of
Japanese encephalitis virus from clinical specimens using a continuous mos-
quito cell line. Am. J. Trop. Med. Hyg. 35:1045–1050.
21. Lum, L. C. S., S. K. Lam, S. Choy, R. George, and F. Harun. 1996. Dengue
encephalitis: a true entity? Am. J. Trop. Med. Hyg. 54:256–259.
22. Solomon, T. 1997. Viral encephalitis in Southeast Asia. Neurol. Infect. Epi-
demiol. 2:191–199.
23. Teasdale, G., and B. Jennett. 1974. Assessment of coma and impaired con-
sciousness. A practical scale. Lancet ii:81–84.
24. Vaughn, D. W., and C. H. Hoke. 1992. The epidemiology of Japanese en-
cephalitis: prospects for prevention. Epidemiol. Rev. 14:197–221.
25. Vaughn, D. W., A. Nisalak, S. Kalayanarooj, T. Solomon, N. M. Dung, A.
Cuzzubbo, and P. L. Devine. 1998. Evaluation of a rapid immunochromato-
graphic test for diagnosis of dengue virus infection. J. Clin. Microbiol. 36:
234–238.
2034 SOLOMON ET AL. J. CLIN. MICROBIOL.
 on June 16, 2013 by U
niversiti M
alaysia S
araw
ak
http://jcm
.asm
.org/
D
ow
nloaded from
 
